Could cutting-edge treatments for select cancers be steered into action against autoimmune disorders and infectious diseases?
The cancer treatments, called CAR-T therapies, involve supercharging immune cells and directing them to attack malignant cells. Only two have been approved so far, and only for certain leukemias and lymphomas. But as scientists and companies seek to expand the types of cancer CAR-Ts target, other researchers are experimenting with adapting them to a host of diseases beyond cancer.
About the Author Reprints
